Epothilones as Natural Compounds for Novel Anticancer Drugs Development

Simple item page
datacite.alternateIdentifier.citationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,Vol.24,,2023
datacite.alternateIdentifier.doi10.3390/ijms24076063
datacite.creatorVillegas, Cecilia
datacite.creatorGonzalez Chavarria, Ivan
datacite.creatorBurgos, Viviana
datacite.creatorIturra Beiza, Hector
datacite.creatorUlrich, Henning
datacite.creatorPaz, Cristian
datacite.date2023
datacite.subject.englishepothilones
datacite.subject.englishepothilone derivates
datacite.subject.englishcytotoxicity
datacite.subject.englishanticancer agents
datacite.subject.englishrefractory cancer
datacite.subject.englishtaxanes
datacite.subject.englishclinical trials
datacite.titleEpothilones as Natural Compounds for Novel Anticancer Drugs Development
dc.date.accessioned2023-06-08T15:48:13Z
dc.date.available2023-06-08T15:48:13Z
dc.description.abstractEpothilone is a natural 16-membered macrolide cytotoxic compound produced by the metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review summarizes results in the study of epothilones against cancer with preclinical results and clinical studies from 2010-2022. Epothilone have mechanisms of action similar to paclitaxel by inducing tubulin polymerization and apoptosis with low susceptibility to tumor resistance mechanisms. It is active against refractory tumors, being superior to paclitaxel in many respects. Since the discovery of epothilones, several derivatives have been synthesized, and most of them have failed in Phases II and III in clinical trials; however, ixabepilone and utidelone are currently used in clinical practice. There is robust evidence that triple-negative breast cancer (TNBC) treatment improves using ixabepilone plus capecitabine or utidelone in combination with capecitabine. In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
dc.identifier.urihttps://repositoriodigital.uct.cl/handle/10925/5287
dc.language.isoen
dc.publisherMDPI
dc.sourceINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
oaire.resourceTypeReview
uct.indizacionSCI
Files
Collections
MigraciĆ³n Web of Science